Author Archives: admin


Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% – – EIN News

Rare Neurological Disease Treatment Market -PMI

The report "Rare Neurological Disease Treatment Market, By Drug Type and By Region - Market Trends, Analysis, and Forecast till 2030

The report "Rare Neurological Disease Treatment Market, By Drug Type (Biologics and Small Molecules), By Mode of Administration (Injectables, Oral and Other Modes of Administration), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Highlights: In 2021, -Global Genes, a prominent international rare illness advocacy organisation, today announced the beginning of a multi-stakeholder programme called Patient Identification and Engagement for RARE CNS Disorders (PIE4CNS). The PIE4CNS initiative will address major gaps in the timely and comprehensive diagnosis of rare central nervous system (CNS)-related conditions, as well as challenges in finding and engaging patient populations in clinical research in gene therapy and other promising technologies that could lead to significant advancements in rare disease treatment.

Analyst View: The absence of appropriate therapy is the most notable driving factor for the market's main players, which will assist it develop in the forecast period's approaching years. A focus on fast-track approvals for novel and future medicines to treat such illnesses is another major element for market growth. Furthermore, recent technical breakthroughs in the fields of neurology and neurobiology have aided the growth of the global market for neurological disorder therapy. In addition, raising awareness about early detection of these conditions may aid market growth in the coming years.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4840

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Outlook for Rare Neurological Disease Treatment Strategies Key Questions this Study will Answer Market Snippet, By Drug Type Market Snippet, By Mode of Administration >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Rare Neurological Disease Treatment Market, By Drug Type, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Biologics Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Small Molecule Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 4.Global Rare Neurological Disease Treatment Market, By Mode of Administration, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Injectables Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Orals Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Global Rare Neurological Disease Treatment Market accounted for US$ 8931.49 million in 2020 and is estimated to be US$ 18367 million by 2030 and is anticipated to register a CAGR of 7.50%. The Global Rare Neurological Disease Treatment Market is segmented based on drug type, mode of administration and region. Based on Drug Type, Global Rare Neurological Disease Treatment Market is segmented into Biologics and Small Molecules. Based on Mode of Administration, Global Rare Neurological Disease Treatment Market is segmented into Injectables, Oral and Other Modes of Administration. By Region, the Global Rare Neurological Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Rare Neurological Disease Treatment Market: CSL Ltd Kedrion Biopharma Inc US WorldMeds LLC Merz Pharma GmbH & Co. KGaA Aquestive Therapeutics Inc Bayer AG Pfizer Inc Novartis AG Merck & Co. Inc. (EMD Serono Inc.) Jazz Pharmaceuticals PLC.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period

Questions answered by Rare Neurological Disease Treatment Market:

1.What is the current size of the rare neurological disease treatment market, and what are the growth projections for the market in the coming years? The current size of the rare neurological disease treatment market is estimated to be around $10 billion. The market is projected to grow at a compound annual growth rate (CAGR) of around 6% during the forecast period from 2021 to 2028, driven by factors such as increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives.

2.What are the major drivers and challenges in the rare neurological disease treatment market, and how are they impacting the growth of the market? The major drivers in the rare neurological disease treatment market include increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives. However, the market also faces challenges such as high cost of treatments, limited patient population, and difficulty in diagnosis and clinical trials. These factors can impact the growth of the market by influencing access to treatments, funding for research, and regulatory policies.

3.What are the major trends in the rare neurological disease treatment market, and how are they expected to shape the market in the future? Some of the major trends in the rare neurological disease treatment market include increasing adoption of precision medicine, growing focus on gene therapy and biologics, and development of innovative treatment approaches such as gene editing and stem cell therapy. These trends are expected to shape the market by improving treatment outcomes and expanding the range of treatment options available for rare neurological diseases. Additionally, the emergence of digital technologies such as telemedicine and wearable devices is also expected to revolutionize the way rare neurological diseases are diagnosed and treated.

Browse Other Related Research Reports from Prophecy Market Insights: Smart Pills Market: By Target Area (Small Intestine, Large intestine, Stomach, and Esophagus), By Application (Drug Delivery, Capsule Endoscopy and Others), By End-Users (Hospitals, Diagnostic Centers, Specialty Clinics and Research Institutes) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Elderly Care Market: By Product Type (Pharmaceuticals, Housing and Assistive Devices), By Service (Institutional Care, Homecare, Adult Day Care), By Application (Heart Diseases, Cancer, Kidney Diseases, Diabetes, Arthritis, Osteoporosis, Neurological, Respiratory and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+1 860-531-2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Read the rest here:
Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% - - EIN News

Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast – EIN News

Pharmerging Market-By PMI

Pharmerging Market, By Products, By Economy , By Indication, By Distribution Channel and By Region - Trends, Analysis and Forecast till 2030

Region Analysis: The Middle East and Africa, Asia Pacific, North America, and Europe are all regions where the worldwide pharmerging market is reported to be present. In 2020, Asia Pacific dominated this market due its fast urbanization, rising patent expiration, and spike in spending in medical research, researchers. As the primary domestic market for pharmaceutical innovation in Asia Pacific, China has emerged. Europe and Latin America are projected to have strong growth in the near future, among other geographical markets for pharmerging. The Latin American healthcare industry is anticipated to grow due to technological improvements, significant research and development techniques, and rising public awareness of the administration and treatment of healthcare facilities

Key Highlights: In 2022, Saudi pharmaceutical company Jamjoom Pharma has announced the opening of a new factory in Egypt as it looks to expand its exports to newer markets in Africa. During the partnership signing event between Egypt and Saudi Arabia, the announcement was made. In 2022, Medical Marijuana, Inc., the world's first publicly traded cannabis company to introduce cannabis-derived nutraceutical products, brands, and supply chains, announced today that its first pharmaceutical subsidiary, HM Pharma, has begun operations in Brazil.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4894

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Pharmerging Market Key Questions this Study will Answer Market Snippet, By Product Type Market Snippet, By Economy Market Snippet, By Indication Market Snippet, By Distribution Channel Market Snippet, By Region >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Pharmerging Market, By Product, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Pharmaceuticals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Healthcare Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 4.Global Pharmerging Market, By Economy , 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Tier-1 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-2 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-3 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 5.Global Pharmerging Market, By Indication, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Lifestyle Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Cancer & Autoimmune Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Infectious Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 6.Global Pharmerging Market, By Distribution Channel, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Hospitals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Clinincs Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Retail Pharmacies Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >E-Commerce Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Drug Stores Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Pharmerging Market size accounted for US$ 971.94 billion in 2020 and is estimated to be US$ 4426.72 billion by 2030 and is anticipated to register a CAGR of 16.5%. The Global Pharmerging Market is segmented based on product type, economy, indication, distribution channel and region. Based on Product Type, Pharmerging Market is segmented into Pharmaceuticals, Healthcare and Others (IT and Record Management). Based on Economy, Pharmerging Market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, Pharmerging Market is segmented into Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease. Based on Distribution Channel, Pharmerging Market is segmented into Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores. By Region, the Pharmerging Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Pharmerging Market: Sanofi S.A. Pfizer Inc. AstraZeneca Plc GlaxoSmithKline Plc F. Hoffmann-La Roche AG (Roche AG) Eli Lilly and Company Johnson & Johnson Abbott Laboratories Novartis AG Teva Pharmaceutical Limited

Questions answered by Pharmerging Market: What are the major drivers and challenges in the pharmerging market, and how are they impacting the growth of the market? The major drivers in the pharmerging market include growing demand for healthcare services, increasing government initiatives for healthcare infrastructure development, rising disposable incomes and middle-class population, and increasing prevalence of chronic diseases. However, the market also faces challenges such as limited healthcare access in remote and rural areas, inadequate healthcare funding, lack of skilled healthcare professionals, and strict regulatory policies. These factors can impact the growth of the market by influencing the development, manufacturing, and distribution of pharmaceutical products in pharmerging markets.

What are the different types of pharmaceutical products available in the pharmerging market, and what are their applications? The different types of pharmaceutical products available in the pharmerging market include branded and generic drugs, biologics, vaccines, and medical devices. These products are used to treat a wide range of diseases and conditions, including infectious diseases, cardiovascular diseases, cancer, diabetes, and respiratory diseases. Additionally, there is an increasing focus on developing innovative therapies such as gene therapy and cell therapy to address unmet medical needs in pharmerging markets. The pharmaceutical products in pharmerging markets are often priced lower than those in developed markets to make them more affordable for the local population.

What are the major distribution channels for pharmerging market products, and how are they evolving? The major distribution channels for pharmerging market products include retail pharmacies, hospitals and clinics, e-commerce platforms, and wholesalers/distributors. In recent years, there has been a shift towards online sales of pharmaceutical products in pharmerging markets, driven by increasing internet penetration and smartphone usage. E-commerce platforms are becoming popular as they provide convenient access to a wide range of pharmaceutical products at competitive prices. Additionally, the use of mobile health (mHealth) technologies for medication management and remote monitoring is also gaining traction in pharmerging markets. However, the traditional distribution channels such as retail pharmacies and hospitals/clinics still play a significant role in the distribution of pharmaceutical products in pharmerging markets, particularly in remote and rural areas with limited internet connectivity.

Browse Other Related Research Reports from Prophecy Market Insights: Prils Market: By Type (Amipril, Quinapril, Cilazapril, Benazepril and Others), By Application (Hypertension, Heart Failure, Chronic Kidney Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Thalassemia Treatment Market: By Type (Alpha-Thalassemia and Beta-Thalassemia), By Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant), By End-User (Hospitals & Clinics, Diagnostic Laboratories and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+ +1 860 531 2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Visit link:
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast - EIN News

Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software – EIN News

Medical Transcription Software Market

Medical transcription software converts digital voice recordings into text that will be used and accessed by medical professionals.

The software can help alleviate the workloads of physicians and ultimately prevent burnout. Nurses, physicians, and doctors dictate or feed voice recordings into the medical transcription solution and the solution produces text and reports that can be stored within a patients digital files.

: https://www.alliedmarketresearch.com/request-sample/31904#UTM_Source=EIN-Mahendra

The global medical transcription software industry generated $1.6 billion in 2021, and is anticipated to generate $7.0 billion by 2031, witnessing a CAGR of 15.5% from 2022 to 2031.

Medical transcription software has a significant scope in hospitals and clinics applications as it can help healthcare professionals streamline their documentation processes, improve accuracy, and reduce administrative workload.

:

Improved accuracy: Medical transcription software uses advanced technologies such as natural language processing and voice recognition to ensure accurate and error-free transcription of medical records.

(254 , , , ) @ https://www.alliedmarketresearch.com/medical-transcription-software-market/purchase-options#UTM_Source=EIN-Mahendra

: The software automates the transcription process, allowing healthcare professionals to save time and focus on patient care. This can result in increased productivity and reduced administrative workload.

: Medical transcription software often comes with advanced security features such as encryption, access control, and backup and recovery options, which can ensure the security and confidentiality of patient records.

: Many medical transcription software solutions can seamlessly integrate with electronic health record (EHR) systems, making it easier for healthcare professionals to access and update patient records.

: By reducing administrative workload and increasing efficiency, medical transcription software can help hospitals and clinics save on operational costs.

- https://www.alliedmarketresearch.com/purchase-enquiry/31904#UTM_Source=EIN-Mahendra

2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly two-fifths of the global medical transcription software market, and is likely to dominate the market during the forecast period. This is attributed to the surge in demand for better healthcare facilities, rise in the demand for medical transcription solution, and government reforms for the acceptance of medical transcription in the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 17.2% from 2022 to 2031. This is owing to the increase in prevalence of chronic diseases, rise in awareness related to the use of medical transcription services, and surge in healthcare expenditure.

: - 3M, Dolbey System, Inc., Global Medical Transcription, DeepScribe, Inc., Microsoft Corporation (Nuance Communication, Inc.), Amazon, Inc. (Amazon Web Services, Inc.), ZyDoc Medical Transcription, SmartMD, AQuity Solutions, iMedX.

- https://www.alliedmarketresearch.com/stem-cell-and-gene-therapy-biological-testing-market-A13443

- https://www.alliedmarketresearch.com/heart-attack-diagnostics-market-A12689

- https://www.alliedmarketresearch.com/huntington%E2%80%99s-disease-treatment-market-A17522

David CorreaAllied Analytics LLP+1 800-792-5285email us here

Original post:
Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software - EIN News

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 … – InvestorsObserver

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030, Says Coherent Market Insights (CMI)

Burlingame, April 04, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global pediatric vaccines market is estimated to be valued at US$ 46,424.3 million in 202 3 and is expected to exhibit a CAGR of 5.9% during the forecast period (202 3 -2030 ).

Analysts Views on Global Pediatric Vaccines Market:

Government authorities in the India are focusing on conducting campaigns in order to provide vaccines to children, and this is expected to drive the growth of the market over the forecast period. For instance, on December 17, 2022, The Pune Municipal Corporation (PMC), India, held a special measles vaccination campaign in which 470 children in pune were immunized. Thus, increasing vaccination campaigns through government authorities can boost the market growth in near future.

Key Trends and Analysis of the Global Pediatric Vaccines Market :

Increasing vaccines approval for pediatric age group by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on October 19, 2022, European Medicines Agency (EMA) recommended approval of Comirnaty and Spikevax COVID-19 vaccines for children of 6 months of age. EMAs human medicines committee (CHMP) has recommended extending the usage of Comirnaty and Spikevax that targets original strain of SARS-CoV-2. The Committee recommended usage of Comirnaty in children aged 6 months to 4 years and usage of Spikevax in children aged 6 months to 5 years. Comirnaty and Spikevax are already approved by EMA for being used in both adults and children aged from 5 and 6 years, respectively.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1708

Global Pediatric Vaccines Market - Driver s

Increasing vaccine approvals by regulatory authorities

Increasing vaccine approvals by regulatory authorities is expected to drive the Global Pediatric Vaccines Market over the forecast period. For instance, on October 15, 2021, Seqirus, a global leader in influenza prevention, and a business of CSL Limited, a biotechnology company announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine), Seqiruss cell-based quadrivalent influenza vaccine for an expanded age indication for children of age six months old. FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine, in the U.S., is now indicated for everyone that is eligible to receive an influenza vaccine in the U.S.

Market players are focused on product evaluation for pipeline product

Market players are engaged in evaluating and demonstrating safety, tolerability, and immunogenicity of vaccines, and this is expected to boost overall growth of the market. For instance, in May 2020, Sanofi, a pharmaceutical and healthcare company has initiated a Phase 2 clinical trial study of pneumococcal conjugate vaccine. Objective of this study is to evaluate immunogenicity and safety of a pneumococcal conjugate vaccine when it is administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.

Pediatric Vaccines Market Report Coverage

Global Pediatric Vaccines Market - Restrain t

Reoccurrence of adverse events after immunization

Although millions of children and adults are vaccinated in order to prevent the occurrence of infectious diseases, such as the Flu, measles, strep throat, COVID-19, and salmonella, several research studies have evaluated reoccurrence of some adverse events after influenza vaccination. Such adverse events are associated with the most common adverse reactions to live or attenuated influenza vaccine (LAIV) are runny nose or nasal congestion in all ages, fever >100F in children 2-6 years of age, and sore throat in adults. Reoccurrence of adverse events after immunization results in declining interest of people for booster dose of influenza vaccines. Therefore, such incidences can pose major challenges such as decreasing community acceptance for vaccines, and this is expected to negatively affect the pediatric vaccines market growth.

Global Pediatric Vaccines Market - Opportunity

I ncreasing government campaigns for immunization program in various region

The government authorities are focusing on the immunization programme in lower-income countries in order to provide healthcare services, and to control the prevalence rate of infectious diseases, and thus, this requires increased production of pediatric vaccines that is expected to create opportunities for market players in the development and production of pediatric vaccine. For instance, on October 28, 2022, the Global Alliance for Vaccines and Immunization (GAVI) announced that GAVI is working with governments, communities, in a concerted effort to rollout measles vaccines to vulnerable children across low income countries such as Angola, Liberia, and others. From 2022 through the first half of 2023, Gavi plans to support 22 lower-income countries to undertake measles follow-up campaigns, aiming to reach more than 85 million vaccinated children.

Global Pediatric Vaccines Market Cross Sectional Analysis:

In Vaccine Type, MMR Vaccine segment is dominant during forecast period in North America region due to increasing product approvals by regulatory authorities in the market, and this is expected to drive segment growth over the forecast period. For instance, on June 6, 2022, GSK PLC, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps, and rubella (MMR) in children of 12 months of age and older. Priorix will be available in the U.S. market.

Global Pediatric Vaccines Market Segmentation:

The Global Pediatric Vaccines Market report is segmented into Vaccine Type, Technology, Type, Distribution Channel and Region

Based on Vaccine Type , the market is segmented into Pneumococcal Vaccine, DTP Vaccine, Rotavirus Vaccine, MMR Vaccine, Polio Vaccine, Influenza Vaccine, Hepatitis B Vaccine, Meningococcal Vaccine, Hib Vaccine, and Varicella Vaccine. Out of which, pneumococcal vaccine segment is expected to dominate in global pediatric vaccines market during the forecast period, due to increasing inorganic growth strategies such as collaboration by key players in the market.

Based on Technology , the market is segmented into Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, Recombinant Vaccine. Out of which, Subunit Vaccine segment is expected to dominate in the market over the forecast period, due to increasing launches of Subunit Vaccine is expected to increase the growth of the segment over the forecast period. For instance, in 2020, Abbott, a healthcare company launched a new inactivated quadrivalent vaccine which is subunit vaccine for influenza in India.

Based on Type , the global pediatric vaccines market is segmented into Monovalent Vaccine and Multivalent Vaccine where Multivalent Vaccine segment is expected to dominate in the market over the forecast period due to prevalence of infectious disease.

Based on Distribution Channel , the global pediatric vaccines market is segmented into Government and Private. Of which, Government segment is expected to dominant in the market over the forecast period, due to increasing vaccination campaigns by government authorities.

Among all segmentation, Vaccine Type segment is expected to dominate in the market due to increasing adoption of inorganic growth strategies such as partnership by key market players in order to expand their product portfolio. For instance, in 2021, SEQIRUS., a global influenza vaccine company, announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvant), this influenza vaccine is helps in protecting individuals of six months of age and older against influenza A (H5N1) in the event of a pandemic.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1708

Global Pediatric Vaccines Market : Key Developments

In June 2022, GSK plc., a U.K.-based multinational pharmaceutical and biotechnology company, announced that the U.S. FDA has approved Priorix (Measles, Mumps, and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals of 12 months of age and older.

On June 18, 2022, the Centers for Disease Control and Prevention (CDC) has approved COVID-19 vaccination for young children of age 6 months old that means 20 million children, in the U.S., who are under 5 years are newly eligible for vaccination .

Key Market Takeaways:

Global Pediatric Vaccines Market is expected to exhibit a CAGR of 5.9% during the forecast period due to increasing effectiveness of vaccines developed by market players. For instance, in July 2021, Sanofi, a France-based multinational pharmaceutical and healthcare company, reported that its single-dose vaccine named MenQuadfi met all primary and secondary endpoints in Phase III MEQ00065 study in healthy toddlers for preventing invasive meningococcal disease (IMD), a fatal illness. The study compared the immune response against meningococcal serogroup C, and analyzed the safety of MenQuadfi in healthy toddlers aged 12 to 23 months against quadrivalent ACWY (four common types of meningococcal bacteria) vaccine, Nimenrix, and monovalent C vaccine, NeisVac-C.

Among Vaccine Type, pneumococcal vaccine segment is dominant due to increasing number of clinical trials for drug development, and this is expected to drive the segment growth over the forecast period. For instance, in April 2022, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

On the basis of Distribution Channel, government segment is expected to hold a dominant position over the forecast period, owing to increasing immunization campaigns in hospital by government authorities. For instance, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) announced that all children of age 6 months to 5 years of age should receive a COVID-19 vaccine. This expands eligibility for vaccination to nearly 20 million additional children, and all Americans ages 6 months and older are now eligible for vaccination. Distribution of pediatric vaccinations for these younger children has started across the U.S. country, and will be available at thousands of pediatric practices, pharmacies, Federally Qualified Health Centers, local health departments, clinics.

Competitive Landscape:

Key players operating in the Global Pediatric Vaccines Market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.

Market Segmentation:

Related Market Intelligence Reports:

Plasmid DNA Manufacturing Market , By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 2030

Single-Use Bioreactor Market , By Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), By Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins, and Other Molecule Types), By End User (Pharmaceutical and Biopharmaceutical Industries and Contract Research Organizations (CRO) Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter

Read the rest here:
Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 ... - InvestorsObserver

Uveal Melanoma Market is estimated to increase with a CAGR of 7.8% during the forecast period-By PMI – EIN News

Uveal Melanoma Market-By PMI

The report "Uveal Melanoma Market, By Diagnosis, By Therapy, By End-User, and By Region - Market Trends, Analysis, and Forecast till 2030

The report "Uveal Melanoma Market, By Diagnosis (Ultrasonography, Indocyanine green angiography, High resolution ultrasound Biomicroscopy and Others), By Therapy (Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others), By End-User (Hospital, Ambulatory surgical centers, Ophthalmology clinics and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Highlights: Immunocore Limited and Eli Lilly and Company announced on June 29, 2015 that they have formed an immunotherapy-based clinical trial partnership to test the efficacy of Immunocore's lead T cell receptor-based research therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib for the treatment of melanoma (LY2801653). In June 2018, Aura Biosciences, a biotechnology company focused on developing therapies that use viral capsid conjugates to target and selectively destroy cancer cells, released interim safety and efficacy data from an open-label Phase 1b/2 study of AU-011 for the treatment of primary choroidal melanoma.

Analyst View: The global market for uveal melanoma treatment is being driven by an increase in the number of cases of eye cancer. One of the key causes of the growth is assumed to be the rise in the use of technological devices. This could be linked to the harmful UV radiation emitted by cellphones, tablets, desktops, laptops, and other electronic devices. According to the American Cancer Society, adults aged 60 and up spend 5 or more hours each day on digital devices and prefer laptops and desktops for internet browsing. As a result, the uveal melanoma treatment market is expected to grow.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4726

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Outlook for Uveal Melanoma Strategies Key Questions this Study will Answer Market Snippet, By Diagnosis Market Snippet, By Therapy Market Snippet, By End-User Market Snippet, By Region >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Uveal Melanoma Market, By Diagnosis, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Ultrasonography Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Indocyanine green angiography Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >High resolution ultrasound Biomicroscopy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

6.Global Uveal Melanoma Market, By Therapy, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Radiation therapy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Surgical resection techniques Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Transpupillary thermotherapy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 7.Global Uveal Melanoma Market, By End-User, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Hospitals Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Ambulatory surgical centers Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Ophthalmology Clinics Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: The Global Uveal Melanoma market is anticipated to register a CAGR of 7.8%. The Global Uvea Melanoma Market is segmented based on the diagnosis, therapy, end-user, and region. By Diagnosis, the Global Uveal Melanoma Market is segmented into Ultrasonography, Indocyanine green angiography, High resolution ultrasound Biomicroscopy and Others. By Therapy, the market is segmented in Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others. By End-User, the Global Uveal Melanoma Market is segmented into Hospital, Ambulatory surgical centers, Ophthalmology clinics and Others. By Region, the Global Uveal Melanoma Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest Uveal Melanoma Market share.

Competitive Landscape: Eli Lilly &Co Novartis AG Bayer AstraZeneca Amgen Pfizer Inc Roche Spectrum pharmaceuticals Many companies in the uveal melanoma treatment industry are attempting to expand their product offerings. However, the most effective way to increase the number of customers is to market the goods through internet portals. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning. Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period.

Questions answered by Uveal Melanoma Market: What are the major factors driving the growth of the uveal melanoma market? The major factors driving the growth of the uveal melanoma market include increasing incidence of the disease, rising awareness and early detection, advancements in diagnostic techniques, and development of new therapies for the treatment of uveal melanoma. Additionally, the growing research on the disease biology and genetics is expected to lead to the development of more targeted and effective therapies for uveal melanoma in the future.

What are the implications of changes in healthcare policy and reimbursement for the uveal melanoma market? Changes in healthcare policy and reimbursement can have significant implications for the uveal melanoma market. These changes can impact the availability and affordability of treatments for patients, as well as the profitability of companies that develop and market these treatments. For example, changes in reimbursement policies may impact the pricing and access to therapies, and may also influence the development of new treatments. Additionally, changes in healthcare policy may impact the funding of research and development efforts related to uveal melanoma.

What are the key trends in the uveal melanoma market, such as new technologies and treatment approaches? The key trends in the uveal melanoma market include the development of new targeted therapies and immunotherapies, advancements in diagnostic techniques, and the increasing focus on personalized medicine approaches. Additionally, there is growing interest in the use of combination therapies and the development of biomarkers to help predict patient response to treatment. Emerging technologies such as gene therapy, RNA interference, and nanotechnology are also being explored as potential treatments for uveal melanoma.

Browse Other Related Research Reports from Prophecy Market Insights: Sandhoff Disease Treatment Market: By Type (Infantile, Juvenile and Late onset), By Treatment (Medication and Surgery), By Therapy (Gene therapy, Enzyme replacement therapy, Stem cell therapy and Others), By End-user (Hospital, Homecare, Specialty Clinics and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Rotavirus Prophylaxis Market: By Treatment (Rotavac, Rotarix, Rotavin-M1 and Others), By Route of Administration (Oral, Parenteral and Others), By End-user (Hospital, Homecare, Specialty centers and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+ +1 860 531 2574email us hereVisit us on social media:FacebookTwitterLinkedIn

See original here:
Uveal Melanoma Market is estimated to increase with a CAGR of 7.8% during the forecast period-By PMI - EIN News

Medical Tubing Market Research Report 2022 | Analysis, Trends, Business Growth and Forecast 2027 – EIN News

Medical Tubing Market Research Report

The global medical tubing market size reached US$ 11.72 Billion in 2021. By 2027, it will reach a value of US$ 18.18 Billion, growing at 7.30% (2022-2027).

Medical tubing refers to flexible, thin, plastic hoses that meet medical industry standards and requirements for a variety of surgical or pharmaceutical applications. It comprises tubes of various lengths and diameters integrated with catheters, peristaltic pumps, anesthesiology, respiratory equipment, intravenous (IV) therapy, and numerous biopharmaceutical laboratory equipment. It also consists of feeding tubes, which are essential for supplying nutrients to people who cannot get enough nutrition by eating or suffering from neurologic and neuromuscular disorders. Medical tubing is manufactured from polyethylene, polyvinyl chloride (PVC), and polypropylene plastic and is often softened with plasticizers to increase flexibility. It helps drain and collect urine from the bladder, monitor the urine output of patients, diagnose disorders in the lower urinary tract, and introduce various medications into the body. Medical tubing also assists in stenting or decompressing the small intestine to reduce pressure and address adhesion in affected areas and treat small bowel obstruction. It is utilized to drive catheters in cardiac catheterization and test for heart diseases and locate narrowing blood vessels. It is also used for measuring pressure and oxygen levels in different parts of the heart, checking pump functions, and diagnosing congenital heart defects. Furthermore, as it allows clinicians to administer fluid and other devices, the demand for medical tubing is increasing around the world.

Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/medical-tubing-market/requestsample

Medical Tubing Market Trends and Drivers:

At present, the rising demand for medical tubing as it is safe, reliable, and temperature resistant represents one of the primary factors influencing the market positively. Besides this, the increasing occurrence of various chronic disorders requiring detailed surgeries and treatment methods, along with the growing geriatric population across the globe, is offering a favorable market outlook.

In addition, the rising occurrence of respiratory diseases and cardiovascular complications caused by excessive smoking habits and breathing polluted air is propelling the growth of the market. Apart from this, increasing rates of hospitalization due to the rising occurrence of various novel viruses causing contagious diseases is contributing to the growth of the market. Additionally, there is a rise in the number of hospitals, clinics, and nursing homes worldwide providing quality healthcare services to patients.

This, coupled with the increasing advancement in improving diagnosis and treatment procedures for various life-threatening conditions, is supporting the growth of the market. Moreover, the rising utilization of medical tubing in the treatment of various forms of cancer, such as breast, prostate, cervical, lung, blood, and brain, is strengthening the growth of the market. Furthermore, the increasing usage of nano-medical tubes in advanced drug delivery systems, such as intracochlear and photo-thermally triggered drug delivery, is bolstering the growth of the market.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/medical-tubing-market

Global Medical Tubing Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Medical Tubing Companies:

ATAG spa, Avient Corporation, Bentec Medical, Hitachi Ltd., Microlumen Inc., NewAge Industries Inc., Nordson Corporation, Optinova, Spectrum Plastics Group, TE Connectivity Ltd., Trelleborg AB and Vanguard Products Corporation.

The report has segmented the market on the basis of region, product, structure, application and end user.

Breakup by Product: Silicone Polyolefins Polyvinyl Chloride Polycarbonates Fluoropolymers Others

Breakup by Structure: Single-Lumen Co-Extruded Multi-Lumen Tapered or Bump Tubing Braided Tubing

Breakup by Application: Bulk Disposable Tubing Drug Delivery Systems Catheters Biopharmaceutical Laboratory Equipment Others

Breakup by End User: Hospitals and Clinics Ambulatory Surgical Centers Medical Labs Others

Breakup by Region: North America: (United States, Canada) Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America: (Brazil, Mexico, Others) Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report: Market Performance (2016-2021) Market Outlook (2022- 2027) Porters Five Forces Analysis Market Drivers and Success Factors SWOT Analysis Value Chain Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse Other Related Reports:

Cholera Vaccines Market Report 2023-2028 : https://www.imarcgroup.com/cholera-vaccines-market

Blood Collection Market Report : https://www.imarcgroup.com/blood-collection-market

Intraoral Scanners Market Report 2023-2028: https://www.imarcgroup.com/intraoral-scanners-market

Gene Therapy Market Report : https://www.imarcgroup.com/gene-therapy-market

X-ray Machine Manufacturing Market Report 2023-2028 : https://www.imarcgroup.com/x-ray-machine-manufacturing-market

C-Arms Market Report : https://www.imarcgroup.com/c-arms-market

Hospital Stretchers Market Report :https://www.imarcgroup.com/hospital-stretchers-market

Biobanking Market Report 2023-2028 : https://www.imarcgroup.com/biobanking-market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact Us:

IMARC Services Private Limited. 134 N 4th St. Brooklyn, NY 11249, USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Anand RanjanIMARC Services Private Limited+1 6317911145email us here

View original post here:
Medical Tubing Market Research Report 2022 | Analysis, Trends, Business Growth and Forecast 2027 - EIN News

AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary – Yahoo Finance

Larry Edwards brings more than two decades of experience in executive and commercial leadership roles in the anti-infective space at both biotechnology and large pharmaceutical companies

AiCuris establishes a U.S. subsidiary as part of preparations for commercialization of its lead product Pritelivir

Dr. Holger Zimmermann to transition from CEO to newly created position of Chief Research and Development Officer to drive R&D activities, including ongoing development and expected NDA submission for Pritelivir

WUPPERTAL, GERMANY / ACCESSWIRE / April 4, 2023 / AiCuris Anti-infective Cures AG, a leading clinical stage pharmaceutical company in the development of novel, resistance-breaking anti-infective agents for the treatment of severe and potentially life-threatening infectious diseases, today announced the appointment of Larry Edwards as Chief Executive Officer (CEO), effective April 1, 2023. Mr. Edwards is an experienced executive with a strong track record of financing and building net cash positive biopharmaceutical companies, as well as successful M&A. He joins with excellent leadership capabilities and will be responsible for driving AiCuris' growth strategy as well as managing its overall operations. Mr. Edwards will also be President of the Company's newly formed subsidiary, AiCuris U.S. Inc., located in Massachusetts. In this role, he will be responsible for establishing the Company's U.S. presence and preparing for commercialization of AiCuris' lead proprietary product candidate, Pritelivir. Mr. Edwards will be based in the U.S.

Mr. Edwards succeeds Dr. Holger Zimmermann, who has successfully led AiCuris as CEO since 2015, and is now taking over the newly created position of Chief Research and Development Officer (CRDO). In this role, Dr. Zimmermann will continue to be responsible for the future focus and direction of the Company's R&D activities and will oversee AiCuris' advanced anti-infective development pipeline, including Pritelivir, which is currently in a pivotal phase 3 trial for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. Should the phase 3 trial be successful, he will oversee the related New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA).

Story continues

"It is my pleasure to welcome Larry as our new CEO. With his exceptional background knowledge in the field of anti-infectives, his proven track record of implementing transformational change at companies and his commercialization expertise, he is the perfect match to lead AiCuris on its planned path of becoming a globally active, profitable pharmaceutical company," said Dr. Stefan Oschmann, Chairman of the Board of AiCuris . "On behalf of the Board, I also would like to take the opportunity to warmly thank Holger for his outstanding contribution as CEO. During his tenure, the Company successfully established itself as the powerhouse for anti-infectives. We saw the approval and market launch of PREVYMIS (letermovir), a groundbreaking drug to prevent CMV infections in immunocompromised patients that had been co-invented by Holger, developed at AiCuris and outlicensed to MSD. Under Holger's leadership of AiCuris, the next promising candidate, Pritelivir, moved into pivotal phase 3 clinical development and is now preparing for data read-out and NDA submission. On behalf of the entire AiCuris Board, we are very proud to work with such a high caliber executive board and to support shaping the future of this exciting company."

Larry Edwards brings more than two decades of experience in operations and commercial leadership roles in the anti-infective space at both biotechnology and large pharmaceutical companies. Prior to joining AiCuris, Mr. Edwards served as President and CEO of publicly traded La Jolla Pharmaceuticals, which he successfully sold and integrated into Innoviva, Inc. Before that, he was CEO of Tetraphase Pharmaceuticals, which was acquired by La Jolla in 2020. Prior to that he worked for Cubist Pharmaceuticals and Merck & Co., Inc. for over 16 years, in a variety of Global and US commercial and leadership roles with escalating responsibilities. Mr. Edwards has an MBA from Boston University and a BS in kinesiology & healthcare administration from Ohio University.

Larry Edwards, newly appointed CEO of AiCuris, commented: "I very much look forward to working with the AiCuris team and leading the Company into an exciting future. With its advanced development pipeline, including a candidate in phase 3 clinical development, as well as a licensed product on the market, the Company is well positioned to become a leader in the field of anti-infectives. I am grateful to have the opportunity to join such a dynamic company focused on improving therapeutic outcomes for patients with life-threatening diseases and to build and execute its strategies for strong growth and success."

About AiCuris Anti-infective Cures AG

AiCuris, a clinical-stage biopharmaceutical company focuses on the discovery, development, and delivery of innovative, anti-infectives drugs to patients with severe infections. The company has developed a commercial drug as well as broad pipeline of clinical-stage and pre-clinical anti-viral and anti-bacterial product candidates. Its lead product PREVYMIS (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized in the EU, US, Japan, China and other parts of the world for the prevention of human CMV infections in immunocompromised patients who received allogeneic hematopoietic stem cell transplantation. Its wholly owned product candidate, pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. Therapeutic candidates for the treatment of other viruses such as BK virus and adenovirus are in earlier stages of development, as are antibacterial product candidates for antimicrobial resistance (AMR), sepsis and topical applications.

AiCuris is supported by a strong shareholder base, including lead investor SANTO Holding.

For more information, please visit http://www.aicuris.com .Follow us on LinkedIn.

CONTACTS:

Company: AiCuris Anti-infective Cures AG Katja WoestenhemkePhone: +49 202 317 63 0Email: press@aicuris.com

Media relations MC Services AG Dr. Solveigh MhlerPhone: +49 211 529 252 19Email: aicuris@mc-services.eu

SOURCE: AiCuris Anti-infective Cures AG

View source version on accesswire.com: https://www.accesswire.com/747497/AiCuris-AG-Announces-Appointment-of-Larry-Edwards-as-Chief-Executive-Officer-and-Formation-of-US-Subsidiary

Originally posted here:
AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary - Yahoo Finance

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications – Yahoo Finance

Genenta Science

MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications, subject to governmental consent as described below.

"We are pleased to reaffirm Genenta's collaboration with OSR by expanding our license agreement and providing our platform access to all solid tumor indications," said Pierluigi Paracchi, Chief Executive Officer of Genenta. "This agreement will strengthen the breadth of our IP position and confirm options for combination treatments and other potential payloads. Promising preliminary clinical data generated in the ongoing study of our first solid tumor indication in glioblastoma supports our decision to expand the license to cover all solid tumors and primes our ability to impact other hard-to-treat cancer types."

The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temferon, which was originally developed by a team led by Genenta co-founder Luigi Naldini in the SR-Tiget laboratories, a world-leading cell and gene therapy research institution formed in a joint venture between OSR and Fondazione Telethon.

The amendment and restatement of the existing OSR agreement with Genenta is subject to Italy's Golden Power Regulation and will not be effective until the applicable Italian governmental authority consents to the amendment and restatement (such consent will be deemed given after the statutory period lapses without any response from the governmental authority). Further, the amended and restated license agreement stipulates that if such consent or deemed consent from the governmental authority is not granted within 90 days of the execution date of the agreement, the amendment and restatement will not be effective, and the original license agreement will remain in place.

Story continues

About Genenta Science Genenta (www.genenta.com) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon, which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.

Forward-Looking StatementsStatements in this press release contain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as anticipate, believe, contemplate, could, estimate, expect, intend, seek, may, might, plan, potential, predict, project, suggest, target, aim, should, "will, would, or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genentas current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the phase 1/2a clinical trial or any studies relating to the treatment of glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM). Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled Risk Factors in Genenta's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta Science S.p.A. undertakes no duty to update such information except as required under applicable law.

Read the original here:
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications - Yahoo Finance

Innovative research draws more than 5000 to annual SOT conference – Environmental Factor Newsletter

Advances in neurotoxicology, research into the developmental origins of health and disease, and numerous presentations by NIEHS scientists and grant recipients were among the many highlights at this years Society of Toxicology (SOT) conference.

The 62nd Annual SOT Meeting and ToxExpo was held in Nashville, Tennessee, March 19-23. More than 90 institute scientists, trainees, and staff shared scientific innovations at the event, which drew more than 5,000 attendees from the U.S. and around the world.

The potential for new discoveries involving liquid biomarkers was the focus of this years Hot Topic Session titled Circulating Molecular and Cell-Derived Biomarkers for Translational Toxicology. Scientists may one day be able to monitor or diagnose chronic diseases such as cancer through those biomarkers, which are detectable in body fluids. Called liquid biomarkers, they can reduce reliance on hard-to-reach tissue biopsies.

Erik Tokar, Ph.D., staff scientist in the NIEHS Division of Translational Toxicology (DTT) Mechanistic Toxicology Branch, co-hosted the session, and Julie Foley, health scientist in the same branch, among others, presented research on the topic. Foley highlighted how the combination of liquid biomarker identification and other innovative scientific methods, such as multi-omics, continue to move forward efforts in translational toxicology and precision environmental health.

The NIEHS-led Hot Topic Session demonstrates that we are at the forefront of scientific research and that we are developing important applications, said SOT Vice President Dori Germolec, Ph.D. She is an immunotoxicologist in the DTT Systems Toxicology Branch.

Germolec and others in DTT are working on new approach methodologies (NAMs), which were a major topic at the conference. NAMs are strategies and technologies, such as artificial intelligence and cell-based models, that complement the use of experimental animals. They are being applied to a broad range of areas, such as prioritizing emerging chemicals of concern and understanding disease susceptibility in diverse populations.

Helena Hogberg-Durdock, Ph.D., a staff scientist in the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and an expert in developmental neurotoxicity, presented several posters and continuing education sessions where she explained the real-world application of NAMs.

NAMs can help scientists translate and understand what effects chemical exposures may have on different organs in a human-relevant situation.

We could use this approach to prioritize a class of chemicals, for example, and based on the information we get from a battery of in vitro assays, we can select which are the more concerning chemicals to investigate further, Hogberg-Durdock explained.

Other presentations included the following.

Tokar and Anna Kreutz, Ph.D., a postdoctoral fellow in the DTT Mechanistic Toxicology Branch, presented a poster describing their work on developmental neurotoxicity studies using NAMs. Specifically, they used human stem cells to identify environmental toxicants that affect the development and expression of dopamine. Another poster presentation on the topic of NAMs and developmental neurotoxicity was Tiered testing of Arsenic Developmental Neurotoxicity using Neural Organoid and 2D in vitro Models, presented by visiting fellow, Xian Wu, Ph.D., Darlene Dixon, D.V.M., Ph.D., a group leader in the Molecular Pathogenesis Group; and Tokar.

A symposium titled The Importance of the Placenta in Toxicological Studies was chaired by Thaddeus Schug, Ph.D., health scientist administrator in the NIEHS Population Health Branch. He noted that research into the placenta is key to advancing the scientific framework known as Development Origins of Health and Disease.

The placenta performs many vital roles during development and can provide critical information about the health of the baby and mom, according to Schug. For example, insights into environmental exposures, nutrition, and prenatal health and development can be gained by studying the placenta. Researchers can study the placenta to learn more about health outcomes in both mothers and children. Several NIEHS scientists and grantees presented during the session.

Schug noted that NIEHS participates in the Human Placenta Project, an effort led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The goal is to expand knowledge about placental development, function, and structure.

Neurotoxicity is always a big topic at SOT. This year, one presentation focused on the origins of neurological disease and the neural exposome, delivered by Chief of the Genes, Environment, and Health Branch Cindy Lawler, Ph.D. And a neurotoxicity battery for botanicals was discussed by Mechanistic Toxicology Branch Staff Scientist Chris McPherson, Ph.D.

A large-scale collaboration called The CIAO Project, which includes more than 80 scientists and 50 organizations worldwide, was featured during the conference. The groups latest research regarding the acute and chronic neurotoxicity effects of COVID-19 was shared with attendees.

The blood-brain barrier, for example, should be considered when examining neurological symptoms, together with the sequence of other biological events following viral exposure, explained Hogberg-Durdock. She said that doing so will help scientists understand how an exposure leads to cell damage and then to organ-level effects that result in a noticeable adverse outcome, such as loss of smell, for example. The research framework that assesses that sequence of events is referred to as an adverse outcome pathway.

We are examining what is happening at the cellular, organ, organism, and population level in COVID-19 and have developed four of these adverse outcome pathways for neurological symptoms loss of smell, encephalitis, seizures/epilepsy, and stroke. Then, we explored the modulating factors.

Those factors can include personal demographics such as age but could also be socioeconomic disadvantage or living in polluted communities.

The susceptibility piece is important because we all are different, and we each will respond differently to exposures, Hogberg-Durdock said. Some people are more vulnerable to adverse outcomes than others due to comorbidities or co-exposures.

The CIAO Project will continue to explore the key susceptibilities related to COVID exposures and various outcomes across life-stages, she noted.

Another international effort highlighted at SOT was the joint SOT and Japanese Society of Toxicology (JSOT) Symposium. Germolec hosted this years session titled Novel Insights into Mechanisms of Chemical Carcinogenesis: From Chemical Screening to Tumor Ecosystem Effects.

We hold two joint symposiums every year, Germolec said. There is one in the U.S., and then one at the JSOTs annual meeting, which this year will be in Yokohama, Japan. We take turns deciding on the topic, and two researchers from SOT and two from JSOT are invited to participate on the panel.

This years JSOT will focus on immunotoxicology, and Germolec was invited to present at the conference. The other U.S. invitee is NIEHS grantee Natalie Johnson, Ph.D., from Texas A&M University.

Also, to serve more international audiences, several editors from Environmental Health Perspectives were at the meeting to recruit editors for the soon-to-be-relaunched Journal of Health and Pollution, which will focus on research conducted in low- and middle-income countries.

NIEHS and National Toxicology Program (NTP) Director Rick Woychik, Ph.D., participated in a featured session titled Meet the Directors alongside leaders from the U.S. Environmental Protection Agency and the U.S. Food and Drug Administration.

Woychik also offered opening remarks for an exhibitor-hosted session to discuss the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Strategic Roadmap. Discussions on wrapping up the former five-year plan and receiving public comment for progressing forward were among the highlights. Efforts to advance NAMs and establish greater scientific confidence in them were also discussed.

I am excited about the robust discussion with our many stakeholders on progress ICCVAM has made in implementing the strategic roadmap and how we can tackle the many challenges that lie ahead, said Nicole Kleinstreuer, Ph.D., director ofNICEATM.

NICEATM also launched an updated version of the Integrated Chemical Environment (ICE) dashboard and held several well-attended demonstrations and tutorials for conference attendees at the NIEHS exhibit.

In addition, Woychik, U.S. Food and Drug Administration (FDA) Chief Scientist Namandje Bumpus, Ph.D., and Nigel Walker, Ph.D., chief of the DTT Systems Toxicology Branch, made remarks at an NTP exhibitor-hosted session. They discussed current efforts that are enhancing the interagency partnership and coordination of research activities.

During that session, attended by a standing-room-only crowd, NIEHS Deputy Director Trevor Archer, Ph.D., who also serves as interim DTT Scientific Director, and Bumpus responded to questions about the future of environmental justice within toxicology. They also shared how NIEHS and FDA are looking at diversity, equity, inclusion, and accessibility in the workforce and in regard to work products, including greater transparency in clinical trials and making data more available.

NIEHS program officers and grant administrators hosted several workshops and shared research funding information, and the Office of Communications and Public Liaison hosted the NIEHS booth at the ToxExpo.

We are really happy to be nearly back to pre-pandemic levels in terms of registrants and attendees, and in terms of scientific programming, said Germolec. It was very exciting to see everyone in person in Nashville.

Citation: Hogberg HT, Lam A, Ohayon E, Shahbaz MA, Clerbaux LA, Bal-Price A, Coecke S, Concha R, De Bernardi F, Edrosa E, Hargreaves AJ, Kanninen KM, Munoz A, Pistollato F, Saravanan S, Garcia-Reyero N, Wittwehr C, Sachana M. 2022. The adverse outcome pathway framework applied to neurological symptoms of COVID-19. Cells, 11(21):3411.

See the original post:
Innovative research draws more than 5000 to annual SOT conference - Environmental Factor Newsletter

Diamyd Medical partners with JDRF to advance the DIAGNODE-3 … – BioSpace

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd. The grant will be funded under JDRF's Industry Discovery & Development Partnerships program that focuses on commercialization of therapeutics and devices for the treatment, cure, and prevention of type 1 diabetes and its complications.

"We could not have a better partner than JDRF as we are focusing on rapid advancement of our antigen-specific immunotherapy towards the market," said Ulf Hannelius, CEO of Diamyd Medical. "We expect this collaboration to significantly boost patient recruitment to this international study as well as our commercial preparations."

"JDRF is committed to supporting and advancing disease modifying therapies to delay and reverse type 1 diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF. "We are excited about Diamyd Medical's groundbreaking Phase 3 trial and its potential advancements in the preservation of insulin production for people recently diagnosed with type 1 diabetes."

"JDRF has played a crucial role in many of the most novel therapeutics and devices that have been approved in the field for those with type 1 diabetes," said Mark Atkinson, Ph.D., director of the Diabetes Institute at the University of Florida and Diamyd Medical Board Member. "JDRF's commitment to this Phase 3 program is a validation of the scientific and clinical value of the antigen-specific immunotherapy Diamyd. It also emphasizes the importance of making disease modifying therapies available to everyone affected by this disease."

About Diamyd MedicalDiamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruting patients with recent-onset Type 1 Diabetes in eight European countries and is being preparedto start recruiting patients in the US this summer. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where the Diamyd was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes. A biomanufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen trial in individuals living with Type 1 Diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

About JDRF JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes Type 1 diabetes is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

For further information, please contact:Ulf Hannelius, President and CEOPhone: +46 736 35 42 41E-mail: ulf.hannelius@diamyd.com

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/diamyd-medical-partners-with-jdrf-to-advance-the-diagnode-3-phase-3-trial-in-type-1-diabetes-301789577.html

SOURCE Diamyd Medical AB

View post:
Diamyd Medical partners with JDRF to advance the DIAGNODE-3 ... - BioSpace